KY19334
Based on 1 Customer Validation
KY19334 is a CXXC5-DVL inhibitor. KY19334 can activate the Wnt/β-catenin pathway by inhibiting CXXC5-Dvl interaction. KY19334 can inhibit cancer cells proliferation, migration, invasion and transformation by inhibiting CDK1. KY19334 can accelerate wound healing and exert regenerative effects. KY19334 can be used for the researches of cancer, inflammation, metabolic and neurological disease, such as cutaneous squamous cell carcinoma and diabetes.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.78%
- No. CAS: 2319609-67-9
- Fòrmula: C17H13N3O3
- Peso molecular:307.30
-
Almacenamiento:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
|
CDK1 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
6.2 μM
Compound: 18b
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 24 hrs by alamar blue assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 24 hrs by alamar blue assay
|
[PMID: 28743492] |
KY19334 (5 μM, 72 h) inhibits the proliferation of human cutaneous squamous cell carcinoma (cSCC) cells HSC-1 and HSC-5, but exerts no significant proliferation inhibition on normal keratinocyte HaCaT cells[1].
KY19334 (5 μM, 24 h) significantly inhibits the migration and invasion of HSC-1 and HSC-5 cells[1].
KY19334 (5 μM, 2 weeks) inhibits the colony formation of HSC-1 and HSC-5 cells[1].
KY19334 (5 μM, 24 h) downregulates CDK1 expression and inhibits the Wnt/β-catenin signaling pathway in HSC-1 and HSC-5 cells[1].
KY19334 (1 mM, 7-16 days) activates the Wnt/β-catenin signaling pathway in keratinocytes, vascular endothelial cells, and fibroblasts of wound tissues from diabetic mice[2].
KY19334 (1 mM, 7 days) promotes the expression of angiogenesis-related proteins in CD31+ vascular endothelial cells of diabetic mouse wound tissues[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HSC-1 and HSC-5 cells
-
Concentration:5 μM
-
Incubation Time:24 h
-
Result:Reduced CDK1 levels by approximately 50%.
Did not alter the expression of CDK4.
Increased the phosphorylation of β-catenin at Ser33/37/Thr41.
Downregulated the expression of downstream target genes c-Myc and Cyclin D1.
-
Cell Line:CD31+ vascular endothelial cells of diabetic mouse wound tissues
-
Concentration:1 mM
-
Incubation Time:7 days
-
Result:Increased VEGFA secretion (approximately 80%), CD31+ capillary density (approximately 75%) and VEGFR2 protein level (approximately 65%).
Downregulated the expression of anti-angiogenic factor Serpin F1 (PEDF) (approximately 50%).
KY19334 (1 mM, topically application, daily for 16 days) accelerates wound healing in diabetic C57BL/6 mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DMBA (HY-W011845)/TPA-induced skin cancer C57BL/6 mice models[1]
-
Dosage:2 mM
-
Administration:Topically application, 30 mins before each TPA
-
Result:Decreased tumor numbers and average size.
Improved tumor grading.
Reduced the proportions of hyperplasia, papilloma and carcinoma in situ.
Decreased the proportion of SCC.
Downregulated the expressions of CDK1, β-catenin, c-Myc, Cyclin D1 and PCNA in tumor tissues.
Upregulated the expressions of tumor suppressor proteins p21Cip/WAF and p27.
-
Animal Model:HFD (high fat diet)+STZ (HY-13753)-induced diabetic C57BL/6 mice and db/db mice[2]
-
Dosage:1 mM
-
Administration:Topically application, daily for 16 days
-
Result:Increased the wound closure rate.
Enhanced collagen deposition in wound tissues.
Restored the proliferation of Keratin14+ keratinocytes and CD31+ capillary density.
Increased nuclear β-catenin expression.
Chemical Information
-
No. CAS 2319609-67-9
-
Appearance Solid
-
Peso molecular 307.30
-
Fòrmula C17H13N3O3
-
Color Purple to purplish red
-
SMILES
O=C(NC1=C/2C=C(OC)C=C1)C2=C3NC4=CC=CC=C4C/3=N\O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvente y solubilidad
DMSO : 103 mg/mL (335.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (289 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Lee SH, et al. Novel small molecules downregulate CDK1 expression and inhibit Wnt/β-catenin signaling in cutaneous squamous cell carcinoma by targeting its distinct tumor-specific cellular landscape. Exp Mol Med. 2025 Sep;57(9):1996-2009. [Content Brief]
[2]. Kim E, et al. Inhibiting the cytosolic function of CXXC5 accelerates diabetic wound healing by enhancing angiogenesis and skin repair. Exp Mol Med. 2023 Aug;55(8):1770-1782. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2541 mL | 16.2707 mL | 32.5415 mL | 81.3537 mL |
| 5 mM | 0.6508 mL | 3.2541 mL | 6.5083 mL | 16.2707 mL | |
| 10 mM | 0.3254 mL | 1.6271 mL | 3.2541 mL | 8.1354 mL | |
| 15 mM | 0.2169 mL | 1.0847 mL | 2.1694 mL | 5.4236 mL | |
| 20 mM | 0.1627 mL | 0.8135 mL | 1.6271 mL | 4.0677 mL | |
| 25 mM | 0.1302 mL | 0.6508 mL | 1.3017 mL | 3.2541 mL | |
| 30 mM | 0.1085 mL | 0.5424 mL | 1.0847 mL | 2.7118 mL | |
| 40 mM | 0.0814 mL | 0.4068 mL | 0.8135 mL | 2.0338 mL | |
| 50 mM | 0.0651 mL | 0.3254 mL | 0.6508 mL | 1.6271 mL | |
| 60 mM | 0.0542 mL | 0.2712 mL | 0.5424 mL | 1.3559 mL | |
| 80 mM | 0.0407 mL | 0.2034 mL | 0.4068 mL | 1.0169 mL | |
| 100 mM | 0.0325 mL | 0.1627 mL | 0.3254 mL | 0.8135 mL |
KY19334 Related Classifications
HY-178227 Related Classifications
Powered by Bioz